MAP0004, a novel inhaled dihydroergotamine, is effective in the acute management of migraine, according to the results of the phase III FREEDOM-301 study (Aurora et al. Headache 2011; 51:507-517).
Latest News
What is a relevant change in ADAS-cog?
April 11, 2012A 3-point change in the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-cog) score appears to be the minimal clinically relevant change for patients with mild Alzheimer’s disease (Schrag et al. J Neurol Neurosurg Psychiatry 2012;83:171-173).
Oral anti-alpha4-integrin in development
March 14, 2012Firategrast, an oral formulation of a natalizumab-like small molecule, produces a significant reduction in MRI lesions, according to the results of a phase II study (Miller et al. Lancet Neurol 2012; epublished January 5, 2012).
Nicotine produces benefits in MCI
March 14, 2012Administration of transdermal nicotine improves cognitive performance in patients with mild cognitive impairment (MCI), according to the results of a pilot study (Newhouse et al. Neurology 2012;78:91-101).